| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Bioject Medical Technologies Inc. is a leader in the development of needle-free injection therapies with over 25 years of experience improving the administration of liquid medications; pharmaceuticals, vaccines, and biologics. Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. From its early work focused on improving the characteristics of these delivery systems, the Company has created a broad technology platform for delivering a wide range of medications and vaccines to the subcutaneous, intramuscular and intradermal depths. Bioject has developed a portfolio of injection systems based on its core technology, the foundation for which is more than 80 issued and pending patents and an extensive body of technical know-how. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing inexpensive, pre-filled, disposable injection systems. Further validating its technology, Bioject and its partners have the largest volume of published studies using needle-free injection technology systems. Bioject's strategy is to form strategic partnerships with pharmaceutical, biotechnology, and animal health companies. The result is mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of their injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies. Bioject's products are also used in public health, Physicians offices, and in cutting edge biomedical research at leading institutions around the globe.
VisionQuest Biomedical Inc. is a research and development company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets. VisionQuest has developed multiple medical devices with funding from the National Institutes of Health and is now looking to transfer those technologies to the commercial space. Our devices are currently being used in the United States and Latin America.
Bardy Diagnostics, Inc. (bardydx.com) has created a new, state-of-the-art heart monitor known as Carnation Ambulatory Monitor (CAM™) that can be worn comfortably and discreetly for up to 7 days. Unlike many other heart monitors, CAM™ can be worn during exercise or while showering. Its unique, narrow, hourglass shape makes it especially advantageous for the female anatomy. Developed on the principle that non-invasive cardiac monitoring should provide an excellent quality atrial signal, the CAM is designed to be placed along the sternum—over the heart— to optimize P-wave signal capture. The result is improved ECG resolution, providing more information about the heart rhythm which may lead to more clinically actionable diagnoses.
GD USA is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, & Biotech sector.